Global Wilson's Disease Drugs Market 2019-2023

ウィルソン病治療薬の世界市場2019-2023

◆タイトル:Global Wilson's Disease Drugs Market 2019-2023
◆商品コード:IRTNTR30238
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2018年11月22日
◆ページ数:112
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥545,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ウィルソン病治療薬の世界市場について調査・分析し、市場概要、市場環境、ウィルソン病治療薬市場規模、製品別(キレート薬、ミネラル)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・ウィルソン病治療薬の世界市場概要
・ウィルソン病治療薬の世界市場環境
・ウィルソン病治療薬の世界市場動向
・ウィルソン病治療薬の世界市場規模
・ウィルソン病治療薬の世界市場:業界構造分析
・ウィルソン病治療薬の世界市場:製品別(キレート薬、ミネラル)
・ウィルソン病治療薬の世界市場:地域別市場規模・分析
・ウィルソン病治療薬の北米市場規模・予測
・ウィルソン病治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・ウィルソン病治療薬のアジア太平洋市場規模・予測
・ウィルソン病治療薬の主要国分析
・ウィルソン病治療薬の世界市場:意思決定フレームワーク
・ウィルソン病治療薬の世界市場:成長要因、課題
・ウィルソン病治療薬の世界市場:競争環境
・ウィルソン病治療薬の世界市場:関連企業情報(ベンダー分析)

129 pages, October 2018
About this market
The increase in strategic alliances to help market grow. Pharmaceutical companies are engaging in strategic alliances for the development of medications for the treatment of Wilson’s disease. These alliances enhance the R&D activities for new drugs for the treatment of Wilson’s disease. Technavio’s analysts have predicted that the Wilson’s disease drugs market will register a CAGR of almost 6% by 2023.
Market Overview
Increasing introduction of patient assistance programs
Patient assistance programs have been introduced to help patients who lack health insurance or prescription drug coverage to obtain the medications they need.
High cost of treatment
Despite the benefits of chelators, the price of these medicines poses a challenge to the market growth. The high cost of chelators will result in low patient adherence to chelator therapy. This, in turn, will hinder the growth of the global Wilson’s disease drugs market.
For the detailed list of factors that will drive and challenge the growth of the Wilson’s disease drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Bausch Health Companies and Mylan the competitive environment is quite intense. Factors such as the rising increase in strategic alliances and increasing introduction of patient assistance programs, will provide considerable growth opportunities to Wilson’s disease drugs manufactures. Bausch Health Companies, Mylan, Teva Pharmaceutical Industries, TSUMURA and Recordati are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. The strategic alliances enhance the R&D activities for new drugs for the treatment of Wilson’s disease. Such alliances help companies develop new drugs for the treatment of Wilson’s disease. It also helps in the faster development of therapeutic products.’

【資料の目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Chelators – Market size and forecast 2018-2023
• Minerals – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bausch Health Companies
• Mylan
• Recordati
• Teva Pharmaceutical Industries
• TSUMURA
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01:Global rare disease drugs market
Exhibit 02:Segments of global rare disease drugs market
Exhibit 03:Market characteristics
Exhibit 04:Market segments
Exhibit 05:Inheritance of Wilson’s disease
Exhibit 06:Market definition – Inclusions and exclusions checklist
Exhibit 07:Market size 2018
Exhibit 08:Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09:Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10:Five forces analysis 2018
Exhibit 11:Five forces analysis 2023
Exhibit 12:Bargaining power of buyers
Exhibit 13:Bargaining power of suppliers
Exhibit 14:Threat of new entrants
Exhibit 15:Threat of substitutes
Exhibit 16:Threat of rivalry
Exhibit 17:Market condition – Five forces 2018
Exhibit 18:Product – Market share 2018-2023 (%)
Exhibit 19:Comparison by product
Exhibit 20:Chelators: Mechanism of action
Exhibit 21:Chelators – Market size and forecast 2018-2023 ($ millions)
Exhibit 22:Chelators – Year-over-year growth 2019-2023 (%)
Exhibit 23:Minerals – Market size and forecast 2018-2023 ($ millions)
Exhibit 24:Minerals – Year-over-year growth 2019-2023 (%)
Exhibit 25:Market opportunity by product
Exhibit 26:Customer landscape
Exhibit 27:Market share by geography 2018-2023 (%)
Exhibit 28:Geographic comparison
Exhibit 29:Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 30:Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31:Top 3 countries in Americas
Exhibit 32:EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 33:EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34:Top 3 countries in EMEA
Exhibit 35:Country_Legend_2
Exhibit 36:APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 37:APAC – Year-over-year growth 2019-2023 (%)
Exhibit 38:Top 3 countries in APAC
Exhibit 39:Country_Legend_3
Exhibit 40:Key leading countries
Exhibit 41:Country_Legend_16
Exhibit 42:Market opportunity
Exhibit 43:Impact of drivers and challenges
Exhibit 45:Impact of drivers and challenges
Exhibit 46:Vendor landscape
Exhibit 47:Landscape disruption
Exhibit 48:Vendors covered
Exhibit 49:Vendor_analysis
Exhibit 50:Vendor classification
Exhibit 51:Market positioning of vendors
Exhibit 52:Bausch Health Companies – Vendor overview
Exhibit 53:Bausch Health Companies – Business segments
Exhibit 54:Bausch Health Companies – Organizational developments
Exhibit 55:Bausch Health Companies – Geographic focus
Exhibit 56:Bausch Health Companies – Segment focus
Exhibit 57:Bausch Health Companies – Key offerings
Exhibit 58:Bausch Health Companies – Key customers
Exhibit 59:Mylan – Vendor overview
Exhibit 60:Mylan – Business segments
Exhibit 61:Mylan – Organizational developments
Exhibit 62:Mylan – Geographic focus
Exhibit 63:Mylan – Key offerings
Exhibit 64:Mylan – Key customers
Exhibit 65:Recordati – Vendor overview
Exhibit 66:Recordati – Business segments
Exhibit 67:Recordati – Organizational developments
Exhibit 68:Recordati – Geographic focus
Exhibit 69:Recordati – Segment focus
Exhibit 70:Recordati – Key offerings
Exhibit 71:Recordati – Key customers
Exhibit 72:Teva Pharmaceutical Industries – Vendor overview
Exhibit 73:Teva Pharmaceutical Industries – Business segments
Exhibit 74:Teva Pharmaceutical Industries – Organizational developments
Exhibit 75:Teva Pharmaceutical Industries – Geographic focus
Exhibit 76:Teva Pharmaceutical Industries – Segment focus
Exhibit 77:Teva Pharmaceutical Industries – Key offerings
Exhibit 78:Teva Pharmaceutical Industries – Key customers
Exhibit 79:TSUMURA – Vendor overview
Exhibit 80:TSUMURA – Business segments
Exhibit 81:TSUMURA – Organizational developments
Exhibit 82:TSUMURA – Key offerings
Exhibit 83:TSUMURA – Key customers
Exhibit 84:Research framework
Exhibit 85:Validation techniques employed for market sizing
Exhibit 86:Information sources
Exhibit 87:List of abbreviations



【掲載企業】

Bausch Health Companies、Mylan、Recordati、Teva Pharmaceutical Industries、TSUMURA

★調査レポート[ウィルソン病治療薬の世界市場2019-2023] (Global Wilson's Disease Drugs Market 2019-2023 / IRTNTR30238)販売に関する免責事項
[ウィルソン病治療薬の世界市場2019-2023] (Global Wilson's Disease Drugs Market 2019-2023 / IRTNTR30238)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆